Physician profile
Gary Lelli Jr
NPI 1093766032
$262,829.76
in general payments reported to CMS, 2019-2025
7 companies · $1,444 in 2025
The $1,444 reported for 2025 was more than what 81% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $66K · 2021: $31K · 2022: $47K · 2023: $60K · 2024: $35K · 2025: $1,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $47K · Honoraria: $28K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,838 · Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $47,328.59 |
| Honoraria | $28,175.00 |
| Travel and Lodging | $11,170.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,838.04 |
| Food and Beverage | $2,383.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $226,435.87 | 2019-2023 | Tepezza |
| Amgen INC. | $30,364.31 | 2024-2025 | Tepezza |
| Genentech USA, INC. | $4,638.65 | 2024 | |
| Genentech, INC. | $1,150.00 | 2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $151.09 | 2025 | Purified Cortrophin Gel, Iluvien |
| Ocular Therapeutix, INC. | $64.76 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $25.08 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Lelli Jr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.